Pharmaceutical

Sunesis Pharmaceuticals (Nasdaq:SNSS) reported financial results for the fourth quarter and year ended December 31, 2017. Loss from operations for the three months and year ended December 31, 2017 was $6.4 million and $34.4 million, respectively. As of December 31, 2017, cash, cash equivalents and marketable securities totaled $31.8 million. This capital is expected to …

Sunesis Pharmaceuticals (Nasdaq:SNSS) reported financial results for the fourth quarter and year ended December 31, 2017. Loss from operations for the three months and year ended December 31, 2017 was $6.4 million and $34.4 million, respectively. As of December 31, 2017, cash, cash equivalents and marketable securities totaled $31.8 million. This capital is expected to fund the company into early 2019.

As quoted in the press release:

“We are excited about the potential opportunity for our lead program, the non-covalent BTK inhibitor vecabrutinib (SNS-062), to help patients who have developed resistance to covalent BTK inhibitors such as ibrutinib, the current standard of care in treating CLL,” said Dayton Misfeldt, Interim Chief Executive Officer of Sunesis. “This year we expect to see our initial safety and efficacy profile for vecabrutinib in its Phase 1b/2 study in patients as we determine the dose to take into our Phase 2 expansion and other studies. Beyond vecabrutinib, we also look forward to advancements in our proprietary PDK1 program and Takeda-partnered pan-RAF inhibitor program.”

Click here to read the full press release.

MARKETS

Markets
TSX19694.16+74.03
TSXV666.01+1.84
DOW33017.52+214.05
S&P 5004173.73+28.54
NASD12758.46+100.90
ASX7015.60+40.70

COMMODITIES

Commodities
Gold1783.87+9.77
Silver20.44+0.62
Copper3.60+0.04
Palladium2239.00+123.00
Platinum944.00+12.00
Oil89.28+0.27
Heating Oil3.21-0.01
Natural Gas7.65-0.41

DOWNLOAD FREE REPORTS

×